Research Disclaimer: All compounds described are sold exclusively for in-vitro and laboratory research use. Not for unsupervised use. This content does not constitute medical advice.
Anti-aging research has shifted from descriptive geroscience to mechanistic intervention biology over the past decade. The identification of specific hallmarks of aging (Lopez-Otin, Cell 2013; 2023 updated 12-hallmark framework) provides a rational framework for compound selection in longevity research protocols. Research compounds targeting NAD+ metabolism, mitochondrial function, GH/IGF-1 axis decline, and cellular senescence are among the most actively studied.
Hallmarks of Aging Targeted by Research Compounds#
| Hallmark | Target mechanism | Research compound class |
|---|---|---|
| Mitochondrial dysfunction | Complex I/III support; mtDNA integrity | SS-31 (elamipretide), NAD+/NMN |
| Cellular senescence | Senolytic clearance or SASP modulation | Not yet well-established compounds |
| Deregulated nutrient sensing | mTOR, AMPK, sirtuins | NAD+/NMN, MOTS-c |
| Loss of proteostasis | Autophagy activation; UPS function | AMPK activators (indirect) |
| Stem cell exhaustion | Satellite cell and progenitor activation | TB-500, GH secretagogues |
| Altered intercellular communication | Hormonal decline (GH, IGF-1, testosterone) | GH secretagogues, testosterone |
| Disabled macroautophagy | Autophagy flux restoration | NAD+ pathway |
| Chronic inflammation (inflammaging) | IL-6, TNF-α, IL-1β reduction | BPC-157, NAD+ |
Compound Review: NAD+ Precursors#
NAD+ decline with aging:
- NAD+ levels decline ~50% between young adulthood and age 60 in rodent and human tissues
- NAD+ is required by: sirtuins (SIRT1–7), PARP enzymes, CD38 NADase, Complex I of mitochondrial ETC
Research compounds:
- NMN (Nicotinamide Mononucleotide): Direct NAD+ precursor via the NMN → NAD+ route (NMNAT enzymes). IP administration in rodent aging models (Yoshino et al., Cell Metabolism 2011; 2021 longevity extension data)
- NR (Nicotinamide Riboside): Converts via NRK1/2 → NMN → NAD+. More bioavailable orally than NMN in some rodent data
- NAD+ direct administration: Poor cellular uptake (charged molecule); not used in cell-based assays; IV/IP in some animal models
Sirtuin activation: SIRT1 deacetylates PGC-1α → activates mitochondrial biogenesis genes; SIRT3 deacetylates mitochondrial complex I subunits → improves ETC function; SIRT6 promotes DNA repair
Compound Review: Mitochondria-Targeted Peptides#
SS-31 (Elamipretide, D-Arg-2'6'-Dmt-Lys-Phe-NH2):
- Cell-penetrating peptide; selectively concentrates in inner mitochondrial membrane (IMM)
- Mechanism: binds cardiolipin on IMM → stabilizes electron transport chain Complex I and III → reduces electron leak → reduces mitochondrial ROS generation
- Published data: improved mitochondrial function in aged rodents; reduced mtDNA damage; clinical trials in heart failure and Barth syndrome
- Research dosing: 3 mg/kg subcutaneous in rodent aging models
MOTS-c (Mitochondria-derived peptide):
- Encoded in mitochondrial 12S rRNA
- Activates AMPK → reduces anabolic one-carbon metabolism → restores metabolic flexibility
- Mimics effects of exercise on insulin sensitivity and longevity pathways
- Mitohormesis research model: low-dose mitochondrial stress → adaptive response → improved resilience
GH Axis Decline in Aging Research#
Somatopause: Progressive decline in GH pulse amplitude with aging (adolescent GH output ≈3× that of 60-year-old). Corresponding IGF-1 decline → loss of anabolic drive, body composition changes, reduced healing capacity.
GH secretagogue research in aging:
- Ipamorelin: GHSR-1a agonism → GH pulse restoration in aged rodent and non-human primate models; published data on improved body composition
- CJC-1295 (with DAC): sustained GHRH analog → baseline IGF-1 elevation; less pulsatile than ipamorelin alone; combination provides both physiological pulsatility and elevated baseline
- MK-677 (ibutamoren): oral GHSR-1a agonist; 24h GH/IGF-1 elevation; most-studied oral option in aging research
Key aging research endpoints for GH secretagogues:
- IGF-1 (serum): age-matched normal range; treatment-induced change
- Body composition (DEXA): lean mass, fat mass, bone mineral density
- Muscle strength (grip strength, rotarod performance in rodents)
- Hippocampal neurogenesis (BrdU incorporation in aged rodent models)
Anti-Aging Protocol Design Principles#
Multi-target approach: Aging is a multi-hallmark process; single-target interventions have limited effect sizes in aged animals. Research protocols targeting ≥2 complementary hallmarks show greater benefit:
- NAD+ + GH secretagogue: addresses metabolic decline AND hormonal decline
- Mitochondrial peptide (SS-31) + NAD+: both target mitochondrial dysfunction from different angles
Aged animal models:
- Caenorhabditis elegans: rapid lifespan assays (20 days); genetic tools available; not mammalian
- D. melanogaster: 60-day lifespan; easier than mammals; limited translatability
- Rodents (C57BL/6 aged 18–24 months): most translatable; expensive; long protocols
- Senescent cell models: IMR-90 lung fibroblasts at passage 30+; useful for senescence biology compounds
Endpoints:
- Lifespan extension (gold standard, most expensive)
- Healthspan markers: running wheel activity, rotarod, grip strength
- Molecular hallmarks: mtDNA copy number, NAD+/NADH ratio, p21/p16 (senescence), 8-OHdG (oxidative DNA damage)
Research Use Only. JuicedPharma does not provide medical advice.
Published by JuicedPharma Research Team · September 2026 · Category: Growth Hormone
